ecc5004
Small moleculeexperimental
Clinical trial activity
15 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2022 (NCT05654831)
Timeline
Indications
Mechanism of action
- GlucagonANTAGONIST
GLP-1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06988553 | Phase 1 | Jun 17, 2025 | Eccogene Clinical Trials |
| NCT06942936 | Phase 1 | May 28, 2025 | AstraZeneca, Parexel |
| NCT06996886 | Phase 1 | May 22, 2025 | AstraZeneca, Parexel |
| NCT06948747 | Phase 1 | May 6, 2025 | AstraZeneca |
| NCT06857695 | Phase 1 | Mar 6, 2025 | AstraZeneca, Quotient |
| NCT06813781 | Phase 1 | Dec 19, 2024 | AstraZeneca, Fortrea Clinical Research Unit Inc. |
| NCT06742762 | Phase 1 | Dec 17, 2024 | AstraZeneca |
| NCT06703658 | Phase 1 | Nov 2, 2024 | AstraZeneca |
| NCT06579105 | Phase 2 | Oct 8, 2024 | AstraZeneca |
| NCT06579092 | Phase 2 | Oct 8, 2024 | AstraZeneca, Bloom University of Leicester |
| NCT06553599 | Phase 2 | Oct 1, 2024 | AstraZeneca, Bloom University of Leicester |
| NCT06555822 | Phase 1 | Aug 15, 2024 | AstraZeneca |
| NCT06293742 | Phase 1 | Feb 8, 2024 | Eccogene Clinical Trials |
| NCT06268145 | Phase 1 | Feb 6, 2024 | Eccogene Clinical Trials |
| NCT05654831 | Phase 1 | Dec 1, 2022 | Eccogene Clinical Trials |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 11 | 11 | 2 | 2024 |
| Eccogene Clinical Trials | For profit | 4 | 4 | 1 | 2022 |
| Bloom University of Leicester | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Parexel | For profit | 2 | 0 | 1 | 2025 |
| Fortrea Clinical Research Unit Inc. | For profit | 1 | 0 | 1 | 2024 |
| Quotient | For profit | 1 | 0 | 1 | 2025 |
6 organizations
Page 1 / 1